Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.